Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. Review uri icon

Overview

abstract

  • Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.

publication date

  • March 1, 2021

Research

keywords

  • Immune Checkpoint Inhibitors
  • Myocarditis

Identity

PubMed Central ID

  • PMC7919710

Scopus Document Identifier

  • 85102141119

Digital Object Identifier (DOI)

  • 10.1016/j.jaccao.2020.04.012

PubMed ID

  • 33645548

Additional Document Info

volume

  • 131

issue

  • 5